Market Study - The Generic Drugs Market Opportunities, Challenges, Strategies, Forecasts, Research Report 2015-2030: Radiant Insights, Inc A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report. Key Findings: The report has the following key findings:
- Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market Topics Covered: The report covers the following topics: - Generic drugs ecosystem - Market drivers and barriers - Technology, economics and key trends - Pure, branded and super generics - Analysis of key therapeutic areas and leading generic drugs - Regulatory landscape of generic drugs throughout the globe - Industry roadmap and value chain - Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers - Strategic recommendations for ecosystem players - Market analysis and forecasts from 2015 till 2030 Historical Revenue & Forecast Segmentation: Market forecasts are provided for each of the following submarkets and their subcategories: Brand Classification - Pure (Non-branded) Generics - Branded Generics
- Super Generics Therapeutic Area - Antibiotics - Cardiovascular & Hypertension - CNS (Central Nervous System) - Dermatology - Diabetes - Gastrointestinal - Hormonal Drugs - Oncology - Pain Relief - Respiratory - Rheumatology - Others Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market Regional Markets - Asia Pacific - Europe - Middle East & Africa - North America - Latin & Central America Country Markets - Brazil - Canada - China - Egypt - France - Germany - Greece - India - Israel - Italy - Japan - Mexico
- Netherlands - Poland - Portugal - Russia - Saudi Arabia - South Africa - South Korea - Spain - Switzerland - Taiwan - Turkey - UK - USA Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market Key Questions Answered: The report provides answers to the following key questions: - How big is the generic drugs opportunity? - What trends, challenges and barriers are influencing its growth? - How is the ecosystem evolving by segment and region? - What will the market size be in 2020 and at what rate will it grow? - Which countries and submarkets will see the highest percentage of growth? - How big is the market for generic cancer drugs? - How does regulation impact the adoption of generic drugs? - How will branded and super generics impact revenue prospects? - Who are the key market players and what are their strategies? - How will patent expirations of biologics impact the market? - What are the future prospects of approved and non-approved biosimilar drugs? - What strategies should generic and innovator drug manufacturers adopt to remain competitive? Table of Contents 1 Chapter 1: Introduction 14 1.1 Executive Summary 14 1.2 Topics Covered 15 1.3 Historical Revenue & Forecast Segmentation 16 1.4 Key Questions Answered 18
1.5 1.6 1.7 1.8
Key Findings 19 Methodology 20 Target Audience 21 Companies & Organizations Mentioned
22
Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market 2 2.1 2.2 2.3
Chapter 2: An Overview of Generic Drugs 26 What is a Generic Drug? 26 Reserve Engineering: How Are Generics Conceived? 26 The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs? 27 2.3.1 What Defines Bioequivalence? 27 2.3.2 Acceptable Bioequivalence Ranges 27 2.4 The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts? 28 2.5 Economics: Price Comparison 28 2.6 Brand Classification: Pure vs. Branded Generics 29 2.6.1 Pure (Non-branded) Generics 29 2.6.2 Branded Generics 29 2.6.3 Super Generics 30 2.7 Market Growth Drivers 31 2.7.1 Cost Effectiveness and Affordability 31 2.7.2 Low Insurance Premiums 31 2.7.3 Patent Expiry of Innovator Drugs 31 2.7.4 Political & Regulatory Support 32 2.7.5 Global Proliferation & Increasing Demand 32 2.8 Market Barriers 33 2.8.1 Patent Linkage: Delaying Product Launch 33 2.8.2 Complex Product Portfolios 33 2.8.3 Quality Control Issues 33 2.8.4 Intense Competitive Landscape 34 2.8.5 Resistance from Big Pharma Players 34 3 3.1 3.1.1 3.1.2 3.1.3 3.1.4 3.1.5 3.2 3.2.1
Chapter 3: Regulatory Landscape 35 Regional Outlook 35 Asia Pacific 35 Europe 37 Middle East & Africa 38 Latin & Central America 39 North America 40 International Initiatives 41 WHO Guidelines 41
3.2.2 3.2.3
IGDRP (International Generic Drug Regulators Pilot) 41 EMA (European Medicines Agency): Extending Collaboration beyond the EU 42
4 4.1 4.1.1 4.1.2 4.1.3 4.1.4 4.1.5 4.1.6 4.1.7 4.1.8
Chapter 4: Drug Class Availability & Leading Therapies Drug Class Availability 43 Antibiotics 43 Cardiovascular & Hypertension 43 CNS (Central Nervous System) 44 Dermatology 44 Diabetes 45 Gastrointestinal 45 Hormonal Drugs 46 Onocology 46
43
Read Complete Report with TOC @ http://www.radiantinsights.com/research/thegeneric-drugs-market 4.1.9 4.1.10 4.1.11 4.1.12 4.2 4.2.1 4.2.2 4.2.3 4.2.4 4.2.5 4.2.6 4.2.7 4.2.8 4.2.9 4.2.10 4.2.11 4.2.12 4.2.13 4.2.14 4.2.15 4.2.16 4.2.17 4.2.18 4.2.19 4.2.20 4.2.21
Pain Relief 46 Respiratory 47 Rheumatology 47 Other Categories 47 Leading Generic Drugs 48 Acetaminophen (Paracetamol) Alprazolam 48 Amlodipine 48 Amoxicillin 48 Asprin (Acetylsalicylic Acid) Atenolol 49 Atorvastatin 49 Azithromycin 49 Bendroflumethiazide 50 Betamethasone Dipropionate Candesartan 50 Clavulanic Acid 50 Clopidogrel 51 Dexamfetamine 51 Diclofenac 51 Doxycycline 51 Enalapril 51 Enoxaparin Sodium 52 Esomeprazole 52 Fentanyl 52 Fenofibrate 52
48
49
50
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For more information visit: Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://radiantinsights.weebly.com/